EGFR and neoplasm: EGFR mutations identified in blood circulating cell-free DNA (cfDNA) have been shown to similarly predict response to EGFR tyrosine kinase inhibitors in the 1L and 2L treatments of mNSCLC with comparable accuracy to mutations identified via tumor tissue biopsy [22].